NewAmsterdam Pharma (NAMS) Earnings Date & Reports

Key Takeaways

• NewAmsterdam Pharma reported third-quarter 2026 revenue of $19.16 million, up sharply from roughly $0.35 million a year earlier and well above the consensus estimate of about $7.9 million.
• Net loss narrowed to $17.39 million, or $0.14 per share, compared with a $72.01 million loss, or $0.61 per share, in the prior-year quarter.
• The European Commission granted approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe), the first regulatory approval of obicetrapib worldwide.
• Operating loss improved to $44.19 million from $55.14 million a year ago, while research and development expenses rose to $39.36 million.
• You can find more details about NAMS's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• For broader market ideas, explore Trending AI Robots to discover AI-driven trading strategies across the market.

Earnings Context and Why It Matters

NewAmsterdam Pharma is a late-stage biopharmaceutical company developing oral, non-statin therapies for patients with cardiometabolic disease. Its lead asset, obicetrapib, is a cholesteryl ester transfer protein (CETP) inhibitor designed to lower low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Because the company is still building toward commercialization, quarterly results are often read less for profitability than for clinical progress, regulatory milestones, and cash runway. This quarter carried added weight: it arrived alongside the company's first-ever regulatory approval in Europe, making the update a pivotal checkpoint for both the obicetrapib program and investor confidence in the company's commercial path.

Reported Results

For the third quarter ended September 30, 2026, NewAmsterdam Pharma reported revenue of $19.16 million, compared with $0.35 million in the same period a year ago and ahead of the consensus estimate of roughly $7.9 million. Net loss for the quarter was $17.39 million, or $0.14 per share on a basic and diluted basis, versus a net loss of $72.01 million, or $0.61 per share, a year earlier. The loss per share was also narrower than the analyst consensus of about $0.49 per share.

Operating loss improved to $44.19 million from $55.14 million a year ago. Research and development expenses increased to $39.36 million from $30.97 million, reflecting continued investment in the obicetrapib program, while selling, general, and administrative expenses declined to $24.00 million from $24.52 million. For the nine months ended September 30, 2026, revenue totaled $25.91 million, up from $22.47 million a year earlier.

On the regulatory front, the company announced European Commission approval of Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination), representing the first approval of obicetrapib anywhere in the world.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and emerging opportunities more efficiently than manual screening. Explore the AI Screener to streamline your own market research.

Market Reaction and Investor Sentiment

Shares of NewAmsterdam Pharma moved higher following the report, rising roughly 4% in the session as investors weighed the revenue beat and the landmark European approval against the company's still-ongoing losses. The reaction reflected a focus on the regulatory milestone and improving top-line trajectory rather than near-term profitability. Sentiment heading into the print had been cautious after recent quarters, making the combination of a revenue beat and a first approval a notable positive. Still, investor attention remains balanced by the company's continued spending and the binary nature of upcoming clinical data readouts.

Forward Outlook and Key Factors to Monitor

Following this quarter, investors will likely focus on the commercialization launch of Ubeslo® and Evlarco® in Europe, which represents NewAmsterdam Pharma's first opportunity to convert regulatory approval into product revenue. Execution on pricing, reimbursement, and market access will be closely watched as early signals of commercial traction.

A second key catalyst is the interim analysis of the PREVAIL cardiovascular outcomes trial (CVOT), expected in the fourth quarter of 2026. This data readout has the potential to meaningfully shape the clinical and commercial outlook for obicetrapib and is widely viewed as a major, high-impact event for the stock.

Investors should also monitor research and development spending, which continues to rise as the company advances additional trials such as the SPINOZA Phase 2b study, as well as the company's cash position and ability to fund its pipeline. The balance between expanding the clinical program and managing operating losses will remain a central theme for the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations